EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TRAIL splice variant TRAILshort disrupts T cell receptor signaling and promotes immune tolerance in vivo

Shahrzad Jalali, Sekar Natesampillai, Zilin Nie, Ying Zhang, Ismail Can, Aswath P Chandrasekar, Brianna M Hameister, Cristina Correia, Tuantuan V Zhao, Dong-Gi Mun, Enrique Garcia-Rivera, Robert Matson und 13 weitere

Journal of Clinical Investigation · 03.08.2026 · 136 (15)

DOI: 10.1172/jci194449 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.08.2026. Verfasst von Shahrzad Jalali und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases. Hauptthemen laut MEDLINE: Signal Transduction, Immune Tolerance, TNF-Related Apoptosis-Inducing Ligand, Receptors, Antigen, T-Cell. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TRAIL is a TNF family ligand that trimerizes TRAIL-R1 (DR4) or TRAIL-R2 (DR5) to induce apoptosis, necroptosis, and/or NF-κB activation in receptor-bearing cells. We previously identified TRAILshort as a splice variant of TRAIL that lacks cysteine 230, cannot trimerize, and acts as a dominant-negative ligand that blocks TRAIL-mediated apoptosis. TRAILshort is expressed on cell surfaces and within extracellular vesicles, enabling it to confer TRAIL resistance to both producing and bystander cells. In this study, we showed that elevated TRAILshort levels were associated with chronic viral infections, cancer, and autoimmune diseases, suggesting a link to impaired immune regulation. Using unbiased phosphoproteomics and mechanistic studies, we demonstrated that TRAILshort binding to DR5 recruited and activated the phosphatase Src homology region 2 domain–containing phosphatase 1 (SHP-1), leading to zeta-chain-associated protein kinase 70 (ZAP-70) dephosphorylation, disruption of ZAP-70–CD3ζ interactions, and impaired T cell receptor signaling, thereby reducing T cell activation, proliferation, and cytokine production in response to antigen or CD3/CD28 ligation. Genetic or pharmacologic SHP-1 inhibition reverses these effects. In humanized mouse models, TRAILshort promoted the persistence of transformed mouse embryonic fibroblasts (MEFs) and L428 and antagonized CD19-directed CAR T cell activity, revealing TRAILshort as an immunomodulator of T cell function with therapeutic implications, including blocking TRAILshort to restore T cell immunity or delivering TRAILshort to enforce tolerance. TRAILshort, a variant of TRAIL, suppresses T cell function and immune responses in cancer and infectious diseases, highlighting its potential as a therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Signal TransductionImmune ToleranceTNF-Related Apoptosis-Inducing LigandReceptors, Antigen, T-CellAlternative SplicingAnimalsHumansMiceProtein Tyrosine Phosphatase, Non-Receptor Type 6Receptors, TNF-Related Apoptosis-Inducing LigandZAP-70 Protein-Tyrosine KinaseCD3 ComplexT-Lymphocytes

Stichwörter der Autor:innen

AIDS/HIVCellular immune responseImmunologyOncology

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 6TNF-Related Apoptosis-Inducing LigandReceptors, TNF-Related Apoptosis-Inducing LigandReceptors, Antigen, T-CellZAP-70 Protein-Tyrosine KinasePtpn6 protein, mousePTPN6 protein, humanTNFSF10 protein, humanZAP70 protein, humanTnfrsf10b protein, mouse

Autor:innen und Institutionen

  • Division of Infectious Diseases.
  • Division of Hematology.
  • Department of Laboratory Medicine and Pathology, and.
  • Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
  • Formation Bio, New York, New York, USA.

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS
  • NIAID NIH HHS
  • NIAID
  • NCI

Zitieren

APA

Jalali, S., Natesampillai, S., Nie, Z., Zhang, Y., Can, I., Chandrasekar, A. P., Hameister, B. M., Correia, C., Zhao, T. V., Mun, D. G., Garcia-Rivera, E., Matson, R., Krogman, A., Maynes, M. A., Batchelor, R., Monie, D. D., Li, H., Behfar, A., Kenderian, S. S., …, & Badley, A. D. (2026). TRAIL splice variant TRAILshort disrupts T cell receptor signaling and promotes immune tolerance in vivo. Journal of Clinical Investigation, 136(15). https://doi.org/10.1172/jci194449

Vancouver

Jalali S, Natesampillai S, Nie Z, Zhang Y, Can I, Chandrasekar AP, et al. TRAIL splice variant TRAILshort disrupts T cell receptor signaling and promotes immune tolerance in vivo. Journal of Clinical Investigation. 2026;136(15). doi:10.1172/jci194449

BibTeX
@article{Jalali2026,
  author = {Jalali, Shahrzad and Natesampillai, Sekar and Nie, Zilin and Zhang, Ying and Can, Ismail and Chandrasekar, Aswath P and Hameister, Brianna M and Correia, Cristina and Zhao, Tuantuan V and Mun, Dong-Gi and Garcia-Rivera, Enrique and Matson, Robert and Krogman, Ashton and Maynes, Mark A and Batchelor, Robin and Monie, Dileep D and Li, Hu and Behfar, Atta and Kenderian, Saad S and Pandey, Akhilesh and Ansell, Stephen M and Taner, Timucin and Weyand, Cornelia and Billadeau, Daniel D and Badley, Andrew D},
  title = {TRAIL splice variant TRAILshort disrupts T cell receptor signaling and promotes immune tolerance in vivo},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {15},
  doi = {10.1172/jci194449}
}
Kostenlos starten →